2017
DOI: 10.1007/s40506-017-0136-6
|View full text |Cite
|
Sign up to set email alerts
|

Retreatment Options Following HCV Direct-Acting Antiviral Failure

Abstract: OPINION STATEMENT Despite the excellent efficacy of direct acting antivirals (DAA) for hepatitis C virus (HCV), treatment failures do occur. Until recently, retreatment decisions after DAA failure were influenced by the number of available agents, concerns about HCV drug resistance, and lack of data regarding retreatment. Recommended treatment approaches previously depended on limited clinical trials and expert opinion. In this article, we review the current state of the evidence for HCV retreatment after DAA … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
8
0
1

Year Published

2018
2018
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 15 publications
(9 citation statements)
references
References 24 publications
0
8
0
1
Order By: Relevance
“…Recommended treatment approaches previously depended on limited clinical trials and expert opinions. 2 Fortunately, a regimen consisting of a fixed-dose combination of SOF (an HCV-NS5B inhibitor), velpatasvir (VEL) (an HCV-NS5A inhibitor) and a second-generation HCV-protease inhibitor, voxilaprevir (VOX) was approved by the Food and Drug Administration (FDA) in July 2017 3 for retreatment of HCV genotype (GT)1-6 after failure with SOF or other NS5A inhibitors.…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…Recommended treatment approaches previously depended on limited clinical trials and expert opinions. 2 Fortunately, a regimen consisting of a fixed-dose combination of SOF (an HCV-NS5B inhibitor), velpatasvir (VEL) (an HCV-NS5A inhibitor) and a second-generation HCV-protease inhibitor, voxilaprevir (VOX) was approved by the Food and Drug Administration (FDA) in July 2017 3 for retreatment of HCV genotype (GT)1-6 after failure with SOF or other NS5A inhibitors.…”
mentioning
confidence: 99%
“…Since HBV infection was found to be one of the most common risk factors for the development of ICC in the last decade, efforts of a number of doctors and researchers have considered that HBV-associated ICC is a malignancy of distinctive characteristics, including relatively infrequent lymph node metastasis, predominance of male patients, frequent elevation of alphafetoprotein, etc. [2][3][4][5] Most importantly, both the preoperative and postoperative extrahepatic metastases are less common in this subtype, which might have contributed to significantly better survival outcomes of the patients who received AVT by controlling the local recurrence after hepatectomy. 6 Furthermore, in the study by Lei et al 1 results of the multivariate analysis showed that HBV-DNA level was the most underpowered variable for OS and recurrence of the tumor, compared to other variables, such as nodal metastasis, tumor diameter, and tumor number.…”
mentioning
confidence: 99%
“…The recent clinical trials showed that most patients who fail HCV treatment with DAA‐based drugs now have good retreatment options. However, some patients may benefit from resistance testing after DAA treatment failure to select the best treatment option 14 …”
Section: Discussionmentioning
confidence: 99%
“…According to data from recent clinical trials, most CHC patients who failed response to DAA therapy now have excellent retreatment choices 12,13 . Retreatment after therapy failure in DAA‐experienced HCV infected patients could be guided either by resistance testing, by knowing which drugs were previously administered or by the experience of treating physicians 14 . Prior retreatment efforts were limited to longer courses of therapy or the addition of ribavirin.…”
Section: Introductionmentioning
confidence: 99%
“…These may be related to the type of drug used or treatment period according to genotype, and usually occurs in the NS5A or NS3/4A regions of the HCV virus (19) . Nevertheless, recent clinical trial data show that most patients who fail HCV treatment with DAAs have excellent retreatment options since newly approved salvage therapies have become available (20) .…”
mentioning
confidence: 99%